In Osteoporosis Osteoporosis is a common condition that weakens bones, making them fragile and more likely to break. It often occurs in women after menopause or who are taking steroids. This condition can be treated with bone-strengthening medicines. Gemfos Tablet slows down the rate at which bone is broken down in your body. This maintains bone density and reduces your risk of breaking a bone. You can also help improve the strength of your bones by doing regular exercise (especially weight-bearing exercise), eating healthy foods containing calcium and Vitamin D, and reducing your consumption of alcohol and tobacco. Supplements of calcium and Vitamin D3 are also effective.
Caution is advised when consuming alcohol with Gemfos Tablet. Please consult your doctor.
Gemfos Tablet may be unsafe to use during pregnancy. Although there are limited studies in humans, animal studies have shown harmful effects on the developing baby. Your doctor will weigh the benefits and any potential risks before prescribing it to you. Please consult your doctor.
Gemfos Tablet is probably safe to use during breastfeeding. Limited human data suggests that the drug does not represent any significant risk to the baby.
Gemfos Tablet does not usually affect your ability to drive.
Gemfos Tablet should be used with caution in patients with kidney disease. Dose adjustment of Gemfos Tablet may be needed. Please consult your doctor. No dose adjustment is recommended in patients with mild to moderate kidney disease. However, use of Gemfos Tablet is not advised in severe kidney disease patients.
Gemfos Tablet is probably safe to use in patients with liver disease. Limited data available suggests that dose adjustment of Gemfos Tablet may not be needed in these patients. Please consult your doctor.
If you miss a dose of Gemfos Tablet, skip it and continue with your normal schedule. Do not double the dose.
FDC Ltd | B-8, MIDC Area, Waluj - 431 136, Dist. Aurangabad, Maharashtra
Marketer/Manufacturer: Abbott || ₹14.5/tablet (25% cheaper)
No customer reviews yet.
FDA approved prescribing information. Levocitrizine; 1995 [revised May 2007]. [Accessed 01 Apr. 2019] (online) Available from: Read More
European Medicne Agency. Revised assessment report: Ambroxol and bromhexine containing medicinal products. 2015. [Accessed 01 Apr. 2019] (online) Available from: Read More
ScienceDirect. Ambroxol. [Accessed 01 Apr. 2019] (online) Available from: Read More
Levocitrizine. Slough, Berkshire: UCB Pharma Limited; 2007 [revised 27 Mar. 2019]. [Accessed 01 Apr. 2019] (online) Available from: Read More
Marketer/Manufacturer: Medsol India Overseas Pvt Ltd || ₹14.5/tablet (25% cheaper)
Marketer/Manufacturer: Sanofi India Ltd || ₹14.5/tablet (25% cheaper)
Marketer/Manufacturer: Molekule India Pvt Ltd || ₹14.5/tablet (25% cheaper)
Marketer/Manufacturer: Cipla Ltd || ₹14.5/tablet (25% cheaper)
Marketer/Manufacturer: Organic Laboratories || ₹14.5/tablet (25% cheaper)
Marketer/Manufacturer: Medreich Lifecare Ltd || ₹14.5/tablet (25% cheaper)